KT-939 Earns Global Cosmetic Ingredient Recognition: INCI & JNCI Approved

Introduction

KT-939 has recently reached a game-changing moment in skincare science: it has earned both INCI (International Nomenclature of Cosmetic Ingredients) and JNCI (Japanese Nomenclature Cosmetic Ingredient) approvals. This opens the global marketplace to a tyrosinase inhibitor known for its superior brightening, anti-inflammatory, and antioxidant capabilities, now officially recognized for beauty use.

What Is INCI & Why It Matters

The INCI system provides standardized, globally recognized names for cosmetic ingredients, ensuring transparency and regulatory consistency across countries. In October 2024, KT-939 received its INCI designation, Methyloxetanecarbamido Thiazolyl Resorcinol, with a unique Mono ID of 39815. Other common names for this compound besides KX-939 are: OXIMIDOL, KWhite 939, and NexaWhite 939.

JNCI Approval: Pathway to Japan’s Market

In June 2025, KT-939 was formally reviewed and approved by the Japanese Cosmetic Industry Committee, receiving its JNCI designation under the name メチルオキセタンカルバミドチアゾリルレゾルシノール. This key milestone enables KT-939's use in cosmetics across Japan, solidifying its international status.

The Science Behind the Skin Benefits

KT-939 outperforms traditional ingredients like Thiamidol, arbutin, and hydroquinone in clinical tests. It demonstrates potent tyrosinase inhibition (IC₅₀ of 70 nM) and melanin reduction (IC₅₀ of 0.36 µM), up to four times more effective than Thiamidol. It also brings antioxidant (via ARE/NRF2 activation) and anti-inflammatory (reducing IL-1α, IL-6, TNF-α) benefits.

Safety Validated. Globally Ready.

KT-939 has passed a rigorous battery of safety tests that cover acute/dermal toxicity, irritation, allergenicity, phototoxicity, mutagenicity, and more, meeting China’s 2015 Safety Technical Standards and positioning it for widespread global usage.

What This Means for Regenvia & You

• Regulatory Recognition: Availability for use in product formulations worldwide, across EU, U.S., Japan, Korea, and beyond.
• Ingredient Integrity: Consumers benefit from a high-performing brightener designed with both clinical efficacy and melanin-safe care in mind.
• Product Design: This positions Regenvia to formulate truly inclusive brightening products that are safe, scientifically sound, and globally compliant.

KT-939’s INCI and JNCI approvals mark a turning point. It’s no longer just a high-performing tyrosinase inhibitor. It’s an officially recognized, globally deployable cosmetic ingredient. At Regenvia, that means transparent science, inclusive formulation, and clinical integrity in every drop.